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Abstract
The ductus arteriosus (DA) is a fetal shunt that directs right ventricular outflow away from
pulmonary circulation and into the aorta. Critical roles for prostaglandin E2 (PGE2) and the EP4
receptor (EP4) have been established in maintaining both the patency of the vessel in utero and in
its closure at birth. Here we have generated mice in which loss of EP4 expression is limited to
either the smooth muscle (SMC) or endothelial cells and demonstrated that SMC, but not
endothelial cell expression of EP4 is required for DA closure. The genome wide expression
analysis of full term wild type and EP4−/− DA indicates that PGE2/EP4 signaling modulates
expression of a number of unique pathways, including those involved in SMC proliferation, cell
migration, and vascular tone. Together this supports a mechanism by which maturation and
increased contractility of the vessel is coupled to the potent smooth muscle dilatory actions of
PGE2.
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The ductus arteriosus (DA) is a fetal arterial vessel that connects the pulmonary duct to the
aorta. It thus allows the majority of right ventricular output to be directed past the fluid filled
fetal lungs towards the descending aorta and placental circulatory system where oxygenation
takes place. Closure of the vessel is believed to occur in two steps, with the initial
constriction of the vessel largely triggered by an increase in arterial oxygen tension (as
ventilation of the lung is initiated) and by a precipitous drop in PGE2 levels at birth.
Remodeling of the vessels is initiated with the lifting of the endothelium from the internal
elastic lamina, fragmentation of the elastin and migration of smooth muscle cells (SMC) into
the sub-endothelial space [1]. This is followed by dramatic structural changes that result in
the eventual transformation of the vessel into the ligamentum arteriosus.
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The patency of the DA, both in utero and immediately after birth, is sensitive to non-
steroidal anti-inflammatory drugs (NSAIDs) such as indomethacin, which inhibits
cyclooxygenase (COX) activity [2,3]. COX converts arachidonic acid into prostaglandin
endoperoxide (PGH2), a rate-limiting step in all downstream prostaglandin (PG),
prostacyclin, and thromboxane synthesis [4]. Fetal exposure to indomethacin can result in
DA closure in utero [2], and indomethacin treatment can often bring about the closure of a
patent ductus arteriosus (PDA) particularly in premature infants [3]. Furthermore,
prostaglandins, including PGE2 can relax the pre-constricted ductus in vitro and infusion of
PGE2 maintains the patency of the vessel after birth [5,6]. Together these experimental and
clinical findings support a model in which the DA is regarded as having intrinsic tone with
the patency of the fetal vessel in utero dependent on the dilatory actions of prostaglandins;
PGE2 [7]. A dramatic drop in circulating PGE2 levels occurs at birth due to loss of the
prostanoid rich placental capillary beds, and the redirection of the right ventricular output to
the pulmonary circulation where high levels of the PGE2 catabolizing enzyme
hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD), as well as the PGE2 transporter,
PGT are expressed. Transport of PGE2 across the cell membrane is the rate limiting step in
PGE2 catabolism. The importance of PGE2 catabolism in DA closure is supported by the
report that mice lacking either HPGD or PGT Transport of PGE2 die shortly after birth with
a PDA [8,9]. Loss of this vasodilatory mediator would allow the intrinsic tone of the vessel
to close the fetal shunt. The importance of the decrease in PGE2 levels at birth in DA closure
is supported by the finding that mice lacking HPGD die in the perinatal period with PDA
and by a high incidence of PDA in families carrying a mutant allele of this gene [10].
This model in which PGE2 counteracts the normal tone of the vessel is consistent with the
known potent dilatory action of PGE2 [11]. One study suggested that PGE2, through the EP4
receptors present on endothelial cells, can increase eNOS activity increasing NO production
[12]. NO stimulates soluble guanylate cyclase allowing accumulation of cGMP in the SMC
[13]. The dilatory actions of PGE2 have been attributed primarily to two of the four PGE2
receptors, EP2 and EP4 [14]. However, the phenotype of the EP4-deficient (Ptger4−/−) mice
suggests a more complex role for PGE2 in the physiology of this vessel, including the
possible role for this receptor on SMC.
METHODS
In situ hybridization
The Ptger4 cDNA probe was synthesized by rtPCR amplification using primers Ptger4-1F
(5’-GTTTGGCTGATATAACTGGTTAAT-3’) and Ptger4-2R (5’-
ACCTGGTGCTTCATCGACTGGACC-3’) and thymus RNA as a template. The S35-
labeled probes were prepared using a commercially available kit (Ambion). Transverse
sections of 8 to 10µm in thickness were prepared, and in situ hybridization carried out as
described [15].
Genetically Engineered Mouse Lines
Animal protocols were approved by the Institutional Animal Care and Use Committee at
UNC. See supplemental method section S1A and Figure 2a for description of the generation
of a loxP-flanked conditional null Ptger4 allele. The generation of mice lacking EP4 and
EP2 has been described previously [16,17].
The Ptger4+/− mice were maintained on a 129S6 background. C57BL/6 Ptger2+/− mice were
crossed for four generations to 129S6. Recombinase transgenic lines, 129S4/SvJaeSor-
Gt(ROSA)26Sortm1(FLP1)Dym/J (Stock # 003946) were obtained from Jackson Labs [18].
B6.Cg-Tg(Tek-Cre)129Flv/J lines (Stock #004128), referred to here as Tek-Cre mice, were
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crossed for seven generations to 129S6 prior to intercross with mice Ptgerfloxed mice [19].
STOCK Tg(Tagln-Cre)1Her/J (Stock #004746), referred to here as Tagln-Cre, were crossed
for nine generations to 129S6 mice prior to intercross with Ptgerfloxed [20]. Tg(Wnt1-
Cre)11Rth Tg(Wnt1-GAL4)11Rth/J (Stock #003829), referred to here as Wnt1-Cre mice,
were crossed for two generations to 129S6 mice prior to intercross with Ptgerfloxed [21].
B6.C-Tg(CMV-Cre)1Cgn/J (Stock # 006054), referred to as CMV-Cre mice, were
maintained on a BALB/c genetic background [22]. The presence of the Cre recombinase
transgene was identified by using primers specific for Cre recombinase coding sequence
(upper 5’-TTACCGGTCGATGCAACGAGT-3’; lower 5’-
TTCCATGAGTGAACGAACCTGG-3’).
Quantitative Real-time RT-PCR
DA of identical genotypes were pooled (4–8 per sample) prior to RNA extraction, and
cDNA generated using the high-capacity cDNA archive kit (Applied Biosystems). Primers
and probes for quantitative real-time RT-PCR (qPCR) were purchased from Applied
Biosystems and reactions were performed in duplicate with 10ng of cDNA using the
TaqMan PCR Universal Master Mix (Applied Biosystems) and using the Applied
Biosystems 7900 HT Fast Real-Time PCR System. Gene expression was normalized to
either β-2 microglobulin (B2M) or GAPDH. Due to observed changes in GAPDH
expression during DA closure, all genes in DA were normalized to B2M gene. Data were
analyzed using the comparative CT method as described by Applied Biosystems.
Indomethacin treatment, Ductus arteriosus collection and scoring
In some experiment, dams were treated with indomethacin (10µg of indomethacin per 1 g of
weight, i.v.) 18.5 after mating. 6 h later, dams were euthanized and fetuses were recovered.
The patency of DA was determined by visual observation and confirmed by placing slight
pressure on the right ventricle and observing movement of blood through the ductus to the
aorta. In some cases, closure did not extend the entire length of the vessel, however if blood
no longer could cross from the ventricle to the aorta, the vessel was scored as closed. All
scoring was done blinded, the genotype of the fetuses becoming available after the
documentation of the structure of the DA.
Statistical Analysis
Statistical analysis of qPCR was performed using Prism 4 (GraphPad Software).
Comparisons of the distributions were made by unpaired t test unless otherwise noted. Data
are shown as median ± S.E.M. Statistical significance was scored as follow: * p<0.05, **
p<0.01, *** p<0.001. Test of proportions was used to calculate statistical significance of
survival data. Differences in patency of the ductus were evaluated by Fisher’s exact test.
RESULTS
Expression of the EP4 in the ductus arteriosus
Analysis of transverse sections through the DA isolated from a 18.5 day full term fetus with
Ptger4 specific probes showed high levels of expression of Ptger4, the gene encoding EP4,
in this vessel, with an intense signal in the layers containing the SMC (Figure 1A–B). Ptger4
expression in the vasculature is generally highest in the endothelial cells. To examine this
point further and to determine if expression of EP4 by smooth muscle cells was limited to
the DA, longitudinal sections were prepared from the DA of a neonate six hours after birth.
At this point the closure and remodeling of the artery assists in defining the transitions
between the DA and the aorta. Again, high levels of Ptger4 expression were observed in the
SMC layers of the DA (Figure 1C–D). An abrupt change in expression is observed at the
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junction between the SMC of the DA and the aorta, with little to no expression of Ptger4 in
SMC of this vessel. This was confirmed by examination of cross section of the aorta (Figure
1E–F). Similarly, little expression of Ptger4 was detected in the SMC of the pulmonary
trunk (Figure 1G–H). In contrast, expression of Ptger4 in endothelial cells was apparent in
all vessels. Thus in the DA, unlike other greater vessels, Ptger4 appears to be expressed by
both the endothelial cells and the SMC.
To quantify the difference in Ptger4 expression in these muscular arteries, RNA was
prepared from the DA, the adult aortic arch, and adult abdominal aorta of a full term fetus
and subjected to qPCR. Ptger4 transcripts were six times more abundant in the DA than in
either the abdominal aorta or aortic arch (Figure 1I).
Generation of the mice carrying a conditional null Ptger4 allele
To define the contribution of EP4R expression by smooth muscles cells and endothelial cells
to the physiology of the DA we generated a mouse line carrying a loxP-flanked conditional
null Ptger4 allele (Figure 2a and supplemental methods S1A). These animals should allow
us to test various models for the contribution of EP4 on these cells populations to both the
maintenance of the patency of the DA in utero and the constriction and subsequent
remodeling of the vessel at birth (Figure 3). The strategy used in generating the mouse line
is detailed in methods section. Briefly, homologous recombination was used to introduce
loxP sites into the introns flanking exon 2, which encodes the EP4 transmembrane domain,
and the neomycin resistance gene, flanked by FRT sites into intron 2. The resulting locus is
designated Ptger4flox-neo. Mice homozygous for the Ptger4flox-neo allele are viable with
lower levels of Ptger4 transcript lung, aortic arch, abdominal aorta, and DA compare to WT
control, although the decrease in the aortic arch did not achieve statistical significance
(Figure 4). Despite the hypomorphic levels of Ptger4 transcript, mice undergo normal DA
closure. The neomycin gene was excised from intron 2 by breeding to mice expressing FLP
recombinase yielding a Ptger4flox locus. Mice homozygous for Ptger4flox locus are viable,
undergo DA closure, and express normal levels of Ptger4 in all tissue tested (Figure 4). Mice
carrying either a flox or flox-neo Ptger4 allele were bred to CMV-Cre transgenic mice to
generate a mouse line carrying a null allele, Ptger4Δexon2. Mice heterozygous for
Ptger4Δexon2 mutation were in-crossed to confirm homozygous lethality of the allele
generated by Cre-mediated recombination (data not shown).
Endothelial cell-specific loss of EP4 and DA patency
In situ analysis shows Ptger4 expression by endothelial cells (Figure 1), and this finding is
supported by reports indicating that PGE2 can modulate vascular tone through its action on
this cell type. It was therefore of interest to determine whether this expression of Ptger4 also
played a role in either maintaining the patency of this vessel in utero or in the closure of the
vessel after birth. Ptger4flox/flox and Ptger4flox-neo/flox-neo mice were intercrossed with mice
heterozygous for the Ptger4 null allele and carrying a Cre transgene controlled by the
endothelial specific promoter of the Tek gene to generate mice lacking endothelial Ptger4
expression. Although slightly fewer than expected Tek-Cre Ptger4flox/− pups were identified
in the litters, the majority of these underwent DA closure (Table 1).
To verify endothelial specific loss of Ptger4 expression in these mice we examined Ptger4
expression via qPCR in the aortic arch (Figure 5A) and abdominal aorta (data not shown), as
in situ analysis of Ptger4 in these vessels indicated that expression was limited to the
endothelium. Ptger4 expression was significantly reduced in both tissues. In contrast, no
difference in expression of EP4 was observed in the kidney, reflecting the relative small
contribution of the expression of EP4 by this cell type to the total expression of EP4 in this
organ, while in other tissues, including kidney, the level of Ptger4 expression did not
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changed (Figure 5B). To determine whether the DA of these animals retained their
dependence on PGE2 for patency, pregnant dams (18.5E) were treated with NSAID
indomethacin as described in method section and DA of fetuses were scored for patency by
visual observation. Twelve pregnancies contributed to the 89 fetuses examined in this
manner, of which 19 were expected to expression no EP4 receptor on endothelial cells. Of
these 19 fetuses, 10 underwent closure of the DA after in utero exposure to indomethacin. 13
of the 17 pups heterozygous for the null and foxed EP4 gene, but lacking the Tek driven Cre
gene showed closure of the DA. The frequency of DA closure in Tek-Cre Ptger4flox/− mice
was not statistically significant compare the Ptger4flox/− controls (n=12 for dams, 89 for
fetuses, P = 0.177).
In addition to EP4, endothelial cells also express the Gs-coupled PGE2 receptor, EP2. This,
together with the slight decrease in the survival of the Tek-Cre Ptger4flox/− suggested the
possibility that the EP2 receptor might play a redundant role in this cell type and compensate
for EP4 loss. We therefore examined the impact of endothelial- restricted loss of EP4 on an
EP2-deficient background. Mice lacking expression of EP2 and EP4 on endothelial cells
were present in litters at expected frequency (See Supplemental Table 1) indicating that the
loss of this additional receptor did not alter the ability of the vessel to remain patent and
support the normal development of the fetus.
Smooth muscle-specific loss of EP4 expression
In situ analysis indicates that the smooth muscle cells of the DA, unlike those of the aorta
and pulmonary trunk express EP4 receptors (Figure 1A–D). We therefore generated mice
carrying the flox or the flox-neo Ptger4 alleles to Ptger4+/− mice and Cre under the control
of the Tagln (Sm22) promoter, which directs Cre expression in both vascular and non-
vascular smooth muscle. We expected that mice expressing the Tagln-Cre and the flox
alleles would lack expression of the receptor in SMC only, allowing us to isolate the
function of EP4 on these cells in DA closure. As seen in table 1, all Ptger4flox-neo/− mice
expressing the Tagln-Cre die in the perinatal period with a PDA indistinguishable from that
observed in Ptger4−/− mice. Loss of EP4 in SMC was confirmed by qPCR analysis of RNA
isolated from the DA of wild type mice, Ptger4flox/− mice, Ptger4flox/− Tagln-Cre mice, and
Ptger4−/− pups (Figure 5C). As expected, no expression of the Ptger4 was detected in the
Ptger4−/− pups. Low but significant expression of the gene was detected in DA of the
Ptger4flox/− Tagln-Cre mice. This is consistent with the undisturbed expression of EP4 on
endothelial cells in the Tagln-Cre mice. However, not surprising, given the muscularity of
this vessel, the expression of Ptger4 by the Tagln-Cre Ptger4flox/− mice was dramatically
lower than that observed in the wild type DA. A much small decrease in Ptger4 expression
was observed in kidneys isolated from same animals, (Figure 5D and this change failed to
achieve statistical significance. This small change is consistent with the cell type specific
loss of Ptger4 expression and reflects the relatively low amount of smooth muscle cell in this
organ compared to other cell types. To determine whether the loss of expression of the
receptor on the SMC altered the response of the vessel to loss of PGE2, two pregnant dams
were treated with indomethacin and the patency of the DA was scored in 18.5-day fetuses.
The DA of the two E18.5 day fetuses with SMC restricted loss of EP4 remained patent in
the absence of PGE2, while closure was observed in littermates with normal EP4 expression.
Loss of EP4 in Neural crest derived SMC
Tagln drives expression of Cre in all SMC, not only those of the DA. This raises the
possibility the PDA observed in the Tagln-Cre Ptger4flox/− mice reflects the combined effect
of the loss of expression of this gene on multiple SMC populations. To address this
possibility we generated mice in which loss of Ptger4 expression was limited to neural crest-
derived cell, the primary embryonic origin of the SMC of the DA and other great arteries of
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the heart [23]. Mice homozygous for either the flox or flox-neo Ptger4 allele were crossed
with Ptger4+/− mice carrying the Cre transgene driven by the Wnt-1 promoter. Neural crest-
Ptger4−/− mice succumb to cardiovascular failure secondary to a PDA (Table 1).
Identification of PGE2/EP4 dependent gene expression in the DA
To gain a mechanistic understanding of the contribution of EP4 on the SMC to both closure
of the vessel at birth and to the dilatory actions of PGE2 in utero, we carried out expression
analysis of DA from full term Ptger4−/− and Ptger4+/+ fetuses. We reasoned that differences
in the expression of genes in Ptger4+/+ DA compare toPtger4−/− DA would identify
pathways whose activities were either directly or indirectly altered by exposure of the DA to
PGE2 and activation of the EP4 receptor. While no gross morphological differences are
observed between the DA of Ptger4+/+ and Ptger4−/− fetuses, we were surprised to find that
gene expression analysis by Illumina microarray revealed 282 transcripts with statistically
significant differential expression between the DA from Ptger4+/+ and Ptger4−/− 18.5 day
fetuses [p < 0.05, fold change > 1.25; see Supplemental Data, Table 2 and 3, for a list of all
282 differential expressed transcripts]. Many of the genes identified have been implicated in
SMC growth, migration and interestingly in determination of both vascular tone and
contractile apparatus (Table 2). We further analyzed expression of 14 as being present at
higher levels in the DA of wild type mice compared to those lacking EP4R by quantitative
PCR. The genes were chosen based on both the fold change observed in the microarray and
the assigned p value. We reasoned that these genes were likely to include genes whose
expression was induced by PGE2/EP4 signaling during maturation of the DA. cDNA
prepared from the aorta was included in the study for additional comparison. This artery,
similar to the DA from the Ptger4−/− animals does not express EP4R in muscle. It would
not be unreasonable to expect that the expression of genes induced by PGE2 and thus
abundant in the wild type DA would be at similar levels in the aorta and the Ptger4−/− DA,
since the smooth muscle of both tissues lack EP4 receptors. We considered the level of
expression in the Ptger4−/− DA as “baseline” assigning it a value of one, and asked whether
the expression of EP4R significantly increased the expression of the fourteen genes.
Significant difference in expression between the Ptger4−/−, DA and wild type DA was
observed for 11 of the 14 gene: Bmper, Bves, Col8a1, Cxcl1, Cxcl15, Egln3, Epgn, Myh11,
Mylpf, Npr3, and Wisp2. No difference was observed for Pvalb, Ryr3, and Tcfap2b (data
not shown). For the majority of the genes examined, higher levels of expression are
observed in the Ptger4+/+ DA compared to the Ptger4+/+ aorta consistent with the hypothesis
that expression of EP4 by the smooth muscle leads to this increase in gene expression
(Figure 6).
Previous studies have identified a critical role for myocardin in expression of contractile
genes by the DA. We therefore compared the 11 genes that differed significantly in
expression between Ptger4+/+ and Ptger−/− (p>.05) to genes regulated by Myocd pathway
using Ingenuity Systems Pathway Analysis (Table 2, myocardin sensitive genes). Since loss
of Myocd by the DA results in a PDA in mice [23], we examined expression of this
transcription factor. Although, no difference was detected by microarray analysis, qPCR
analysis of Ptger4−/− and wild type DA showed a 50% reduction in expression of Myocd in
the Ptger4−/− tissue relative to the wild type DA. In the case of these Myocd regulated genes,
EP4 expression appears to be required to maintain expression at levels similar to those
observed in other muscular arteries.
Discussion
Our studies show that the EP4 is highly expressed by cells located in the media of the DA
and that EP4 expression serves as a marker for this great artery, distinguishing it from the
adjoining pulmonary truck and aorta. Using mouse lines with SMC and endothelial cell
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restricted loss of EP4 we provide evidence supporting both a dilatory and developmental
function for this receptor, with both of these actions mediated through the EP4 on the SMC.
The expression of EP4 by endothelial cells including those of the DA is consistent with a
model in which EP4 activation leads to production of dilatory mediators that act on the
underlying SMC maintaining the patency of the vessel (Figure 3). However, while such a
model accounts for the ability of PGE2 to maintain the patency of the DA in utero and after
birth, it is not consistent with our finding that fetal expression of the EP4 by endothelial cells
is not required for the normal development. Pups lacking endothelial EP4 are present in
litters at birth and normal DA closure indicates that the vessel has matured and is capable of
constriction and remodeling. In addition, maternal exposure to indomethacin results in DA
constriction in these fetuses.
PGE2 can mediate relaxation of other smooth muscle through Gs couple receptors. For
example, relaxation of airway smooth muscle is mediated through the Gs coupled EP2 [24].
The observation that a rapid decrease in PGE2 levels can lead to rapid closure of the DA,
either at birth or in response to maternal indomethacin treatment, suggests that PGE2 does
act, at least in part, through similar dilatory pathways in the DA. However, if this
represented the only function of SMC EP4 pathways, premature closure of the vessel in
utero would be expected in the Tagln-Cre Ptger4flox/− animals.
Taken together, the pharmacological and genetic studies suggest that a more complex model
is required to describe the contribution of the EP4 to DA physiology. The SMC of the DA
are derived from the neural crest progenitors, cells that also contribute substantially to the
SMC of aorta and carotid arteries. However, unlike the SMC of the aorta, DA SMC acquire
unique properties including the ability to proliferate and contribute to intimal cushion
formation particularly in larger species and the ability to migrate to the sub-endothelial
space facilitating the remodeling of the vessel at birth. Concurrent with these changes the
vessel must remain patent in utero yet be capable of constricting in response to rise in
oxygen tension at birth. Our analysis of genes expressed by DA lacking EP4 indicates that
PGE2 signals through this receptor to direct expression of a diverse set of genes, many of
which would be expected to contribute to the acquisition of these functional characteristics.
EP4-dependent expression of a number of genes expected to contribute to SMC migration
was observed. Notable among these was collagen VIII, which displays chemotaxtic
properties and supports migration, adhesion and focal adhesion formation of SMC [25]. One
of the most dramatic differences in the expression profile of Ptger4−/− and wild type DA was
in the expression of the chemokine Cxcl15. Although, no role for SMC migration has been
identified for this chemokine, the related ELR-CXC human chemokine, Cxcl5/ENA-78 has
been shown to be inducible by prostanoids and to play a role in mesenchymal cell migration,
metastasis and angiogenesis [26,27]. Blood vessel epicardial substance (Bves) is a
membrane protein that accumulates at points of cell/cell contact [28]. Introduction of this
gene into cells confers adhesive behavior. In addition, its expression is required for coronary
vessel development [29]. Bves−/− mice display delayed skeletal muscle regeneration due to
impaired migration of satellite cells [30]. The higher expression of Bves in the DA
compared to the aorta could reflect a similar function in migration of DA SMC. It is also
interesting to note that the wild type DA express higher levels of fibronectin than those
lacking the PGE2/EP4 pathway. Although this difference was not verified by PCR analysis it
is consistent with early studies showing fibronectin dependent migration of DA smooth
muscle cells [31,32].
PGE2 is known to promote growth of many cell types including murine aortic SMC [33].
PGE2 has also been shown to stimulate vascular endothelial growth factors in human airway
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SMC [34]. However, the mechanism by which PGE2 promotes growth of SMC is not
known. A possible mechanism is suggested by our observation of EP4-dependent expression
of two EGFR ligands, epithelial mitogen and betacellulin (Btc) by the DA (Supplemental
table 2). Expression of epithelial mitogen was approximately three fold higher in the wild
type DA compared to both neighboring aorta and Ptger4−/− DA, suggesting positive
regulation of an epithelial mitogen by PGE2. While little information is available concerning
the functions of epithelial mitogen [35], the related EGFR ligands, EGF, BTC and EPR have
been reported to contribute to the transition of differentiated non-proliferative SMC to cells
capable of growth and migration [36]. EGFR pathways are believed to contribute both to
atherosclerosis and angiogenic changes. The demonstration that PGE2/EP4 can increase
expression of EGFR ligand in the DA suggests that similar pathways may be utilized by
PGE2 to impact vascular remodeling during other conditions, including wound healing,
plaque formation and angiogenesis.
A second possible pathway by which PGE2 could modulate growth and differentiation of
SMC is suggested by the demonstration that PGE2 can enhance the Wnt signaling cascade
through cAMP/PKA-mediated regulation of β-catenin stability [37]. Consistent with this we
note an increase in expression of a number of Wnt transcriptional targets, including
Gremlin-1, Wisp2 (Table 2) and Semaphorin 3C (Supplemental table 2) in the wild type DA
relative to the Ptger4−/− vessel. The largest increase was noted for the WNT sensitive
Gremlin-1 transcript that encodes a secreted bone morphogenic (BMP) protein antagonist
[38]. Interestingly, we also noted an increase in expression of Bmper, a more recently
identified inhibitor of BMP, suggesting that regulating the actions of BMP may be important
in the development of the vessel [39].
The rapid constriction of the DA in the neonate is well documented, and the importance of
the contractility of the vessel is demonstrated by the phenotype of a mouse line that lacks
myocardin expression in SMC of neural crest origin [23]. These pups die in the perinatal
period with a PDA indicating that expression of myocardin and expression of contractile
proteins is essential for DA closure. Consistent with this interpretation, mutations in the
myocardin regulated contractile protein MYH11 are linked to hereditary PDA, and the loss
of MYH11 in mice results in delayed closure of the DA [40,41]. The possibility that the
maintenance of the contractile phenotype of the vessel is at least in part dependent on EP4 is
suggested by difference in the expression of a number of myocardin sensitive transcripts in
Ptger4−/− and wild type animals. Although genome wide analysis did not detect differential
myocardin expression, qPCR analysis indicated that the expression of this transcription
factor was approximately two times higher in wild type DAs compared to DAs collected
from Ptger4−/− pups. This raises the possibility that EP4 expression is required for normal
induction and/or maintenance of myocardin expression, and that increased expression of
Myh11 and Mylpf in wild type DA compare to Ptger4−/− DA is secondary to increased
levels of myocardin. Increased myocardin expression was observed on analysis of
fibroblasts after induction of Wnt signaling [42]. This raises the intriguing possibility that
PGE2 also contributes to the contractile phenotype of the DA indirectly through stabilization
of β-catenin.
While it is possible that all of the dilatory actions of PGE2 are mediated directly through
regulation of SMC cAMP levels, our expression analysis raises the possibility that PGE2
might also regulate genes capable of modulate the dilatory/constriction response of the
vessel. For example, Egln3 is expressed at high levels in the DA compared to the aorta, in an
EP4-dependent manner. Egln3 encodes an intracellular prolyl hydroxylase, which through
its ability to hydroxylate the alpha subunit of hypoxia inducible factor can regulate the
cellular response to oxygen availability [43]. By induction of this gene PGE2 could
contribute to acquisition of an oxygen sensitive contractile response by the DA, enabling the
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vessel to detect and rapidly constrict upon transitional rise of oxygen at birth. The
mechanism for the contractile effects of alterations in oxygen tension on the DA has not
been completely defined. A number of studies have suggested that increased oxygen tension
leads to smooth muscle cell depolarization and an increase in intracellular Ca++ secondary
to closing of oxygen sensitive potassium channels [5]. A possible mechanism by which the
change in oxygen tension can mediate constriction of the DA was suggested by the finding
that oxygen reversibly inhibited a 4-aminopyridine sensitive potassium channel leading to
membrane depolarization and increase in Ca++ by opening of L-type voltage sensitive
channels [44]. No alteration in the expression of L type Ca++ channels was observed in the
EP4 deficient DA in our analysis. Genome wide analysis showed that loss of EP4 resulted in
a decrease in expression of the shaker related potassium channel KCNAB1 whereas
expression of KCNJ8 was increased, although these changes were not verified by PCR
analysis. KCNJ8 has been shown to play a critical role in dilation of coronary arteries and
thus, if this change can be further documented it raises the possibility that EP4 can modulate
the physiology of the DA in part by altering expression of potassium channels.
A number of other agents, in addition to PGE2, capable of relaxing the DA have been
identified [5]. For example, inhibition of nitric oxide synthase (NOS) was shown to result in
contraction of the lamb DA both in vitro and in vivo [45,46]. Further studies using ductuses
in which the endothelial cells were removed suggested that the NO could be derived not
only from the endothelia cells, which we suggest in one of our models, but also from
extraluminal sources [45,47]. Although not confirmed by quantitative PCR, we noted a
small increase in the levels of endothelial NOS (eNOS, Supplemental table 3) in the DA
from the EP4−/− animals. This increase does not support a role for PGE2 upstream of eNOS.
It may in fact represent an attempt of the DA to compensate for the loss of this PGE2 by up-
regulation of an alternate dilatory pathway.
The DA is unique among the great arteries in its expression of extremely high levels of EP4.
Our studies suggest that this expression pattern evolved to allow for rapid alteration of blood
flow at birth, changes required for transition from placental to pulmonary oxygenation of
blood. Expression of high levels of EP4 on DA SMC provided a means by which the
contractile properties, possibly its sensitivity to oxygen, and the DA’s capacity to undergo
remodeling could be modified independent of other arteries. While most studies have
focused on the coupling of EP4R to Gαs and thus its ability to increase cAMP, unlike the
EP2 receptor, activation of EP4 has been reported to lead to phosphorylation of the extra-
cellular signal-regulated kinases (ERKs) by a PI3K dependent mechanism [48]. At this time
it is not possible to determine whether all aspects of the function of EP4 in DA physiology
are mediated by a single pathway. For example, it is possible that the ability of EP4 to
modify gene expression is mediated by the ERK pathway, whereas the dilatory actions are
dependent on increase in cAMP. Also it will be important to determine the time course of
expression of the EP4 receptor during development and establish whether EP4 functions
both to alter gene expression and/or mediate the dilatory actions of PGE2 during all stages of
development. It is not unlikely that expression of EP4 might increase during the last few
days of gestation but then decrease at birth, and that this decrease contributes to the closure
of the vessel.
• Mice deficient in EP4 expression in smooth muscle (SMC) and endothelial cells.
• EP4 expression only in SMC is required for ductus arteriosus (DA) closure.
• Genome wide gene expression analysis of WT and EP4−/− DA.
• Identification of PGE2/EP4 dependent gene expression in the DA.
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Expression of Ptger4 in the ductus arteriosus. (A, B) Transverse sections of DA from the
18.5 day mouse fetus; (C, D) longitudinal sections of DA from neonate; (E, F) transverse
sections of neonatal aorta (6 h after birth); (G, H) transverse section of neonatal pulmonary
trunk; sections were hybridized with 35S labeled Ptger4 antisense probe (A,C,E,G) or Ptger4
sense probe (B,D, F,H). Scale bar is 150µm. Black arrowhead points to junction between the
SMC of the DA and the aorta; white arrowheads depict Ptger4 expression in endothelial
cells. I) Ptger4 transcript levels in abdominal aorta, aortic arch, and DA as measured by
qPCR
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Schematic depicting the generation of a conditional null Ptger4 allele. A) The structure of,
the endogenous Ptger4 locus, the targeting plasmid, and the Ptger4 allele generated by
homologous recombination of the plasmid with the wild type locus and the expected
structures of these alleles in cells expressing either FLP or Cre recombinase, is shown.
Restriction enzymes sites and probes used in identification of cells carrying a correctly
targeted allele are indicated. The loxP and FRT sites are represented by filled and open
triangles, respectively. EcoRI is abbreviated as RI. Filled, numbered boxes represent exons.
B and C Identification of ES cell clones in which the targeting plasmid integrated by
homologous recombination and in which this recombination event results in introduction of
the loxP site into intron 1. Integration of the targeting plasmid by homologous
recombination results in the introduction of an additional ScaI site generating a novel 6.6 kb
Sca1 DNA fragment detectable by a probe located just 3’ of the segment of the Ptger4 locus
used to assemble the targeting construct. While only the Sca1 fragment corresponding to the
endogenous Ptger4 locus is present in DNA shown in lane 1, the presents of a 9.8 and 6.6 kb
fragment in lane 2 indicates that in this cell line one of the two Ptger4 alleles has undergone
homologous recombination with the targeting plasmid. Recombination between the targeting
plasmid and the endogenous locus can occur at any point along regions of homology. To
identify those ES cells in which recombination occurred 5’ to the loxP site in intron 1, a
second screen was carried out on all targeted ES cells. The presence of an EcoRI site in the
linker DNA of the loxP site is expected to reduce the size of the EcoR1 fragment detected by
a probe corresponding to exon 2. This probe detects an endogenous fragment of 5.5 kb and
either a 7.8 kb or 3.7 kb in targeted ES cells lines, with the later fragment indicative of a
crossover event 5’ to the location of the loxP site in intron 1. Although the cell line
corresponding to the DNA analyzed in panel C lane 1 carries a targeted Ptger4 allele, this
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line lacks the loxP site in intron 1. In contrast, the presence of the 3.7 kb EcoR1 fragment in
lane three indicates that in this line intron 2 is flanked by loxP sites. The DNA shown in lane
2 was prepared from an untargeted ES cell line. D. Excision of the floxed Ptger4 exon 2 in
cells expressing Cre recombinase was verified by preparing DNA from mice generated by
intercross of EP4flox mice with mice expressing Cre recombinase in their germline. 8.9 kb
Sca1 fragment detected by the 3’ probe in DNA shown in lane 2 is consistent with Cre-
mediated excision of exon 2 from the targeted allele. The Sca1 fragment generated from the
EP4floxP allele is ~300bp larger than the wild type (WT) allele, due to the presence of the
loxP sites and linker sequences. This small difference in size prevents resolution of these
two alleles on Southern analysis with Sca1.
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Models for the role of the EP4 receptor in the maturation and closure of the ductus
arteriosus. A) DA has intrinsic tone that is counteracted by PGE2 through endothelial EP4
receptors. This model predicts premature closure in EP4 deficient mice. B) No EP4
dependent dilatory signal is required to maintain patency. PGE2/EP4 is responsible for the
maturation of the DA, resulting in increased tone, which is required for closure at birth.
However, this model is not consistent with the ability of indomethacin to rescue Hpgd−/−
mice. If PGE2 had no dilatory function, the loss of PGE2 would not be expected to cause
closure. C) In this model, PGE2 has two roles in the physiology of the DA. First through the
smooth muscle EP4 receptors, PGE2 provides a metabolic signal stimulating maturation. At
the same time, PGE2, through a dilatory signal via the endothelium, counteracts increasing
tone of the DA. However, this model would predict premature closure in mice not
expressing either EP4 or EP2 in the endothelium. D) In this model, PGE2/EP4 provides two
functions. In its absence, the DA fails to mature. Second, as the vessel matures, PGE2
induced relaxation of the smooth muscle independent of the endothelium prevents premature
closure. This model is consistent with the finding that mice lacking expression of EP4 in the
smooth muscle die with a PDA, and mice lacking EP4 in the endothelium and EP2 in both
endothelium and smooth muscle survive with no naïve phenotype. While in the rodent the
source of NO is the endothelium, in larger animals the vasa vasorum, contributes to NO
production. Although a number of agents can dilate the ductus, for simplicity we show only
PGE2.
Symbols in models:
SMC-red shapes, endothelial cells-blue shapes, EP4-yellow receptors, EP2-blue receptors,
activated receptors-yellow highlight.
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Expression of the Ptger4 receptor in mice homozygous for the conditional null Ptger4
alleles. RNA was prepared from the adult (A) lung (n=5), (B) aortic arch (n=4), and (C)
abdominal aorta (n=5), and from the (D) full term (18.5E) DA (n=5) of animals with the
indicated genotype and the expression of Ptger4 assessed by qPCR. Gene expression was
normalized to either GAPDH (A–C) or β-2 microglobulin (B2M) (D). No difference in
expression of Ptger4 was observed between wild type mice and mice carrying the floxed
allele. In contrast the presence of the neomycin gene in intron 2 significantly decreased
expression of Ptger4 in some tissue. Statistical analysis: * p < 0.05.
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Cell lineage restricted loss of EP4R expression. Expression of Ptger4 was examined by
qPCR in (A) aortic arch (n=8), (B and D) kidney (n=6), and (C) DA (n=5) isolated from
animals (E18.5) heterozygous for Ptger4 null, Ptger4flox-neo, and genetically identical
littermates expressing either Tek-Cre (A and B) or Tgln-Cre (C and D). Gene expression
was normalized to either GAPDH (A, B, D) or β-2 microglobulin (B2M) (C). Ptger4 levels
are decreased by approximately 80% in the aorta of mice expressing the endothelial specific
Cre, while no significant change is observed in the kidney. While the majority of Ptger4
expression by the DA is lost in tissue expressing Cre in the SMC, the expression remains
higher than that detected in DA from Ptger4−/− mice, reflecting the continued expression of
Ptger4 by endothelial cells. . Statistical analysis: ** p < 0.01, *** p<0.001.
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Identification of EP4R-dependent gene expression in the DA. Expression of eleven genes
identified by microarray analysis as increased in the wild type DA compared to Ptger4−/−
DA were further analyzed by qPCR. Expression of myocardin was also evaluated because of
its established role in DA closure. Expression of each of the genes in the full term Ptger4+/+
DA and Ptger4+/+ adjacent aorta was compared to expression in Ptger4−/− DA. N=8 for
DA, n=4 for aorta‥ . * p-value < 0.05, **p-value < 0.01, *** p-value<0.001.
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Table 2
Several genes up-regulated in wild type full-term ductus arteriosus versus Ptger4−/− full-term ductus arteriosus
are depicted. Fold increase in wild type ductus arteriosus from microarray analysis indicated in (). Underlined
genes verified by qPCR.
Type Genes
Contractile apparatus Mylpf (2.68), Mylk (1.27), Myh11 (1.27), Myocd (1.84)*
Migration Cxcl15 (6.61), Col8a1 (2.69), Bves (1.93), Adamtsl2 (2.37), Col8a2 (1.66), Cxcl1 (1.42), Cxcl16 (1.29), Cxcr4
(1.28)
Growth Epgn (4.68), Grem1 (2.34), Bmper (2.25), Wisp2 (1.97), Btc (1.59)
Vascular Tone Egln3 (4.68), Npr3 (2.50), Ism1 (1.75), Slc03a1 (1.36)
Myocardin sensitive genes Tpm2 (1.31), Tnnt3 (1.89), Tnni2 (1.73), Tnnc2 (1.71), Tjp1 (1.30), Slc12a2 (1.45), Pdlim3 (1.25), Mylpf (2.68),
Myh11 (1.27)
*
qPCR identified Myocd as differentially expressed, fold change from qPCR; microarray analysis did not identify Myocd as differentially
expressed due to p-value.
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